MX381727B - Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. - Google Patents
Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.Info
- Publication number
- MX381727B MX381727B MX2018004977A MX2018004977A MX381727B MX 381727 B MX381727 B MX 381727B MX 2018004977 A MX2018004977 A MX 2018004977A MX 2018004977 A MX2018004977 A MX 2018004977A MX 381727 B MX381727 B MX 381727B
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic
- treat cancer
- pdk1 inhibitors
- pdk1
- inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100351314 Caenorhabditis elegans pdk-1 gene Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 abstract 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 abstract 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 abstract 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 abstract 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245606P | 2015-10-23 | 2015-10-23 | |
| PCT/US2016/058255 WO2017070565A1 (en) | 2015-10-23 | 2016-10-21 | Heterocyclic pdk1 inhibitors for use to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004977A MX2018004977A (es) | 2018-07-06 |
| MX381727B true MX381727B (es) | 2025-03-13 |
Family
ID=57209945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004977A MX381727B (es) | 2015-10-23 | 2016-10-21 | Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20190015410A1 (enExample) |
| EP (2) | EP3763368A1 (enExample) |
| JP (1) | JP7094879B2 (enExample) |
| KR (1) | KR20180101329A (enExample) |
| CN (1) | CN108697699A (enExample) |
| AU (2) | AU2016342352B2 (enExample) |
| BR (1) | BR112018008025A2 (enExample) |
| CA (1) | CA3002907A1 (enExample) |
| DK (1) | DK3364971T3 (enExample) |
| ES (1) | ES2820770T3 (enExample) |
| MX (1) | MX381727B (enExample) |
| PL (1) | PL3364971T3 (enExample) |
| RU (1) | RU2018118786A (enExample) |
| WO (1) | WO2017070565A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114763326B (zh) * | 2021-01-13 | 2026-01-02 | 南京宁丹新药技术股份有限公司 | 一类氨基酸酯衍生物及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2024040242A1 (en) * | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Combinations of pdk1 inhibitors and kinase inhibitors |
| WO2024040241A1 (en) | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| DE102005061655A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Diazepinone |
| PL2485731T4 (pl) | 2009-10-06 | 2017-07-31 | Millennium Pharmaceuticals, Inc. | Związki heterocykliczne użyteczne jako inhibitory PDK1 |
| WO2011067145A1 (en) * | 2009-12-04 | 2011-06-09 | Nerviano Medical Sciences S.R.L. | Tricyclopyrazole derivatives |
| WO2019094779A1 (en) * | 2017-11-09 | 2019-05-16 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
-
2016
- 2016-10-21 CN CN201680072623.7A patent/CN108697699A/zh active Pending
- 2016-10-21 MX MX2018004977A patent/MX381727B/es unknown
- 2016-10-21 RU RU2018118786A patent/RU2018118786A/ru unknown
- 2016-10-21 CA CA3002907A patent/CA3002907A1/en active Pending
- 2016-10-21 KR KR1020187014416A patent/KR20180101329A/ko not_active Ceased
- 2016-10-21 EP EP20180303.8A patent/EP3763368A1/en not_active Withdrawn
- 2016-10-21 WO PCT/US2016/058255 patent/WO2017070565A1/en not_active Ceased
- 2016-10-21 JP JP2018520428A patent/JP7094879B2/ja not_active Expired - Fee Related
- 2016-10-21 US US15/770,369 patent/US20190015410A1/en not_active Abandoned
- 2016-10-21 EP EP16788389.1A patent/EP3364971B1/en active Active
- 2016-10-21 ES ES16788389T patent/ES2820770T3/es active Active
- 2016-10-21 BR BR112018008025-0A patent/BR112018008025A2/pt not_active Application Discontinuation
- 2016-10-21 PL PL16788389T patent/PL3364971T3/pl unknown
- 2016-10-21 AU AU2016342352A patent/AU2016342352B2/en not_active Ceased
- 2016-10-21 DK DK16788389.1T patent/DK3364971T3/da active
-
2022
- 2022-05-12 AU AU2022203204A patent/AU2022203204A1/en not_active Abandoned
- 2022-06-02 US US17/831,041 patent/US20230099829A1/en not_active Abandoned
-
2024
- 2024-03-11 US US18/600,974 patent/US20240207258A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180101329A (ko) | 2018-09-12 |
| RU2018118786A (ru) | 2019-11-26 |
| PL3364971T3 (pl) | 2021-05-31 |
| US20240207258A1 (en) | 2024-06-27 |
| EP3364971A1 (en) | 2018-08-29 |
| US20230099829A1 (en) | 2023-03-30 |
| BR112018008025A2 (pt) | 2018-10-23 |
| RU2018118786A3 (enExample) | 2020-02-25 |
| US20190015410A1 (en) | 2019-01-17 |
| AU2016342352A1 (en) | 2018-05-10 |
| EP3364971B1 (en) | 2020-06-17 |
| CN108697699A (zh) | 2018-10-23 |
| AU2016342352B2 (en) | 2022-06-02 |
| JP7094879B2 (ja) | 2022-07-04 |
| DK3364971T3 (da) | 2020-09-21 |
| ES2820770T3 (es) | 2021-04-22 |
| MX2018004977A (es) | 2018-07-06 |
| JP2018538244A (ja) | 2018-12-27 |
| EP3763368A1 (en) | 2021-01-13 |
| AU2022203204A1 (en) | 2022-06-02 |
| CA3002907A1 (en) | 2017-04-27 |
| WO2017070565A1 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551760A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| CL2021003513A1 (es) | Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer. | |
| ZA202000148B (en) | Heterocyclic inhibitors of atr kinase | |
| PH12018500177A1 (en) | Compositions useful for treating disorders related to kit and pdfgr | |
| PH12017501817B1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| PH12017501925A1 (en) | Pyrazole compounds and method for making and using the compounds | |
| MY202026A (en) | Compounds useful as kinase inhibitors | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12017502050B1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| EA201890884A1 (ru) | Способ и композиции для нежелательных и аномальных мышечных сокращений | |
| MX2016005393A (es) | Metodos para tratar vhc. | |
| MA39824A (fr) | Composés azole amido-substitués | |
| MX2018004977A (es) | Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. |